The Bioethics Shared Resource (BESR), coordinated through the Tuskegee University National Center for Bioethics in Health Care Research, provides exceptional bioethics education, training, guidance, and consultation for the MSM/TU/UABCCC Partnership. BESR activities fall under two overarching and complementary objectives: (a) achieving competencies in content areas of bioethics, having especially to do with research ethics, and (b) integrating bioethics concepts throughout the Partnership by dialogue with researchers, clinicians, professors, students, mentors, community health advisors, patient navigators, recruiters, and key personnel. Achieving appropriate bioethical competencies and integration ensures that cancer research, outreach, mentoring, and partnering with underserved or minority communities follow ethical guidelines.
Specific Aims are: 1. To provide education, mentoring, and training in bioethics for mentors, faculty, fellows, graduate and undergraduates students, community partners, and other key partnership personnel. 2. To coordinate and teach the Tuskegee University graduate/undergraduate course in bioethics, health disparities and health policy. 3. To instruct and coordinate the continuing yearly course, Bioscience Research and Ethics, for graduate students. 4. To provide review of research projects from design to implementation. 5. To evaluate bioethics education and training needs of all elements of the Partnership, in collaboration with the Cancer Education Program. 6. To collaborate in overall guidance and leadership ofthe Partnership. 7. To collaborate with other Partnership members in conducting and reporting empirical research and publishing scholarly works in relevant bioethics journals as well as lay publications. 8. To collaborate with Partnership members in securing funding for bioethics research, service, and educational activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA118948-08
Application #
8759631
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (O1))
Project Start
2005-09-30
Project End
2016-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
8
Fiscal Year
2013
Total Cost
$5,969
Indirect Cost
$1,845
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Luo, Yanzhuo; Li, Bingjin; Zhang, Guangxin et al. (2018) Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion. J Cancer 9:1096-1105
Wang, Chiung-Min; Yang, William H; Liu, Runhua et al. (2018) FOXP3 Activates SUMO-Conjugating UBC9 Gene in MCF7 Breast Cancer Cells. Int J Mol Sci 19:
Moore, Justin Xavier; Royston, Kendra J; Langston, Marvin E et al. (2018) Mapping hot spots of breast cancer mortality in the United States: place matters for Blacks and Hispanics. Cancer Causes Control :
Akinyemiju, Tomi; Moore, Justin Xavier; Pisu, Maria et al. (2018) A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality. Obesity (Silver Spring) 26:193-201
Akinyemiju, Tomi; Moore, Justin Xavier; Judd, Suzanne E et al. (2018) Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget 9:16099-16109
Piyathilake, Chandrika J; Badiga, Suguna; Borak, Samuel G et al. (2017) A higher degree of expression of DNA methyl transferase 1 in cervical cancer is associated with poor survival outcome. Int J Womens Health 9:413-420
Williams, Samuel K; Braxton, Joanne M; Gosdin, Melissa et al. (2017) Evidence-Based Care for the Elderly: Uses of ""the Grandmother Principle"". J Health Care Poor Underserved 28:7
Gao, Song; Wang, Yicun; Wang, Meng et al. (2017) MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Oncotarget 8:41451-41464
Jia, Xu; Shanmugam, Chandrakumar; Paluri, Ravi K et al. (2017) Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. Oncotarget 8:20198-20212
Zhang, Yifan; Li, Bingjin; Zhang, Xingyi et al. (2017) CD24 is a genetic modifier for risk and progression of prostate cancer. Mol Carcinog 56:641-650

Showing the most recent 10 out of 193 publications